Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Theranostec Inc
Profile last edited on: 8/30/2019      CAGE: 7QZG9      UEI: M65HLKKKBJ41

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2015
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

9944 Nestling Circle
Elk Grove, CA 95757
   (530) 220-2322
   N/A
   N/A
Location: Single
Congr. District: 07
County: Sacramento

Public Profile

Theranostec Inc is working on the following projects: 1. Paclitaxel loaded Nanoparticles for ovarian cancers 2. Development of Nanoparticles to eradicate pediatric brain cancers 3. Full-API self-assembled nanoparticle for imaging-guided diagnosis and treatment of oral cancers.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
2
Conversion Rate
50.00%
Phase I Dollars
$1,216,893
Phase II Dollars
$2,479,899
Total Awarded
$3,696,792

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,630,042
Project Title: Transformable Nano-Theranostics for Image-Guided Interventions in Head and Neck Squamous Cell Carcinoma
2022 1 NIH $399,999
Project Title: Sub-100 nm and scalable self-therapeutic nanoparticles to target autophagy in pancreatic cancer
2020 2 NIH $2,291,539
Project Title: Extremely Long Tumor Retention, On-Demand Releasing Nano-Taxel for Eradicating Ovarian Cancers
2018 1 NIH $225,000
Project Title: Ninja Theranostics for Overcoming the Drug Delivery Barriers to Pediatric Brain Tumor

Key People / Management

  Paul Thomas Henderson

  Yuanpei Li

  Tzu-Yin Lin

Company News

There are no news available.